Biotech, Food & Drug

HB Ad Slot
HB Mobile Ad Slot

In today’s hyper-aware environment, concerns about food and drug safety are paramount for both companies and consumers.  The Food and Drug Administration (FDA) and the US Department of Agriculture (USDA) regulates the areas of biotech, food, and drug law. Additionally, laws including the 21st Century Cures Act, and cGMP (Current Good Manufacturing Processes), regulate industry standards/norms in food, cosmetics, and other industry-sectors. Visitors to the National Law Review will find the latest analysis of news, legislation, and upcoming cases/litigation as it relates to this area of law.

With researchers searching for new energy solutions and other developments in biotech, visitors to the NLR will have the opportunity to read content surrounding biosimilars, natural fuel production, medical devices, biotechnology, nanotechnology and materials, and the pharmaceuticals industry. Additionally, content relating to food and drug laws, limits on chemical use in cosmetic products, and other general health/safety topics are covered by the National Law Review and are updated regularly. Additionally, food safety and imports to the United States are also discussed as they become relevant. 

In addition to general health, science, and food/drug, the industry is also closely related to many of the issues related to intellectual property law. New applications for patents, intellectual property, licensing laws, and other areas which are governed by the PTAB court, often crossover into the industry.

New developments in legislation, including the legalization of recreational marijuana has created a new area ripe for legal analysis.  Regulations on how recreational marijuana can be advertised and marketed, distributed and the kind of insurance coverage necessary for dispensaries.  Additionally, employer drug-testing and marijuana statutes have been a hot area of litigation covered by the National Law Review.  

General practices in marketing standards, compliance of federal and state laws/legislation, licensing collaborations, and news related to bringing new products to the market, in the US and abroad, are among the areas visitors to NLR will read about daily. Drug pricing, changes in production standards, regulatory compliance, food safety and handling, drug laws (legalization of marijuana, both recreational and medicinal in the workplace), and labeling and nutritional requirements, are among the many topics covered by the National Law Review daily.

Visitors will always find the latest, up-to-date, most comprehensive coverage on the site. And, news and stories which affect the US, companies which are regulated in the industry, and multinational/international companies, are detailed regularly for NLR readers.

National Law Review Cannabis TwitterFor hourly updates on the latest news about biotech, food & drug, and cannabis laws, regulations, and legislation, be sure to follow our Cannabis X (formerly Twitter) feed, and sign up for complimentary e-news bulletins.

Recent Biotechnology, Food & Drug Administration FDA News

Title
Publication Date Organization Sort ascending
Jul
7
2021
340B Update: Delaware Court Denies 340B Program Statute Requiring Contract Pharmacy Arrangements K&L Gates
May
2
2022
Litigation Minute: Defending Consumer Class Action Claims Involving PFAS K&L Gates
Jul
15
2022
New FDA Draft Guidance Aiming to Prevent Drug Shortages Will Affect Pharmaceutical Manufacturers K&L Gates
Jun
4
2023
Highlights for Research Institutions and Sponsors in FDA's Recent Draft Guidance on Decentralized Clinical Trials K&L Gates
Aug
15
2023
Tea Parties Certified For Class Action K&L Gates
Dec
11
2020
HRSA Publishes Long-Awaited (and Long-Overdue) 340 B Program Alternative Dispute Resolution Process Final Rule K&L Gates
Dec
22
2020
340b Update: Recent Supreme Court Ruling May Curtail 340b Program Discriminatory Pricing K&L Gates
Apr
7
2021
Impact of the Growing Marketing Authorization Holder Pilot Program in China's Medical Device Industry K&L Gates
Apr
20
2021
Cannabis Banking: The Safe Banking Act 2.0 Passes the House of Representatives K&L Gates
Jul
21
2021
Five Things to Know About the Changes to China's Medical Device Regulation K&L Gates
Aug
10
2021
CMS Proposes to Rescind Most Favored Nation Drug Pricing Rule K&L Gates
Nov
19
2021
COVID-19: Florida Curtails Vaccination Mandates for Private Employers K&L Gates
Jun
21
2022
Supreme Court Issues Decision Favorable to Hospitals on 340 B Payment Reduction: What to Do Next K&L Gates
Jul
26
2022
Litigation Minute: Red Lobster Complaint Highlights Threat of ESG Litigation to The Food and Beverage Industry K&L Gates
Apr
24
2020
Court of Chancery Holds That Sole, Conflicted General Partner Cannot, By Reason of Conflict, Delegate Its other Valid Power to Manage Derivative Litigation K&L Gates
Jul
21
2020
340b Update: HRSA Indicates It Lacks Authority to Enforce 340b Program Guidance K&L Gates
Jan
11
2017
Australia Trademark Dispute: An Apple a Day Doesn’t Keep Litigation at Bay K&L Gates
Jan
17
2017
Medical Marijuana Comes to Pennsylvania: What to Expect As the Keystone State Rolls Out its New Medical Marijuana Program K&L Gates
Aug
4
2017
Employees Celebrate Chip Party: Embedding RFID Chips – Would You Agree to This? K&L Gates
Nov
3
2017
Impact of Cyberattack on Merck was $135 million K&L Gates
Aug
31
2022
Cadbury’s Purple Reign: High Court Allows Cadbury to Register Their Iconic Purple Colouring K&L Gates
Mar
28
2023
Technical Effect Embodied In Technical Teaching K&L Gates
Sep
26
2023
In Starch Contrast: Australian Patent Office Makes Key Finding on Use of Trade Marks in Patent Specifications K&L Gates
Mar
5
2024
Highlights from FDA Regulatory Developments in Clinical Trials: 2023 Recap and 2024 Forecast [Podcast] K&L Gates
Jul
27
2020
President Trump Signs Drug Pricing Executive Orders Reinforcing the Administration's Priorities K&L Gates
Sep
26
2020
340B UPDATE: Congress and the Administration Respond to Drug Manufacturers' 340B Contract Pharmacy Actions K&L Gates
Apr
19
2017
Abbott Labs Makes Costly Mistake as FDA Targets Cybersecurity Deficiencies K&L Gates
Apr
2
2021
Cannabis Banking; The SAFE Banking Act 2.0's Status, Key Modifications, and Prospects K&L Gates
 

NLR Logo

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins

 

Sign Up for e-NewsBulletins